Clinical Focus

  • Pediatric Cardiology
  • Pediatric Cardiomyopathy, Heart Failure, and Heart Transplantation

Academic Appointments

Administrative Appointments

  • Director, Cardiomyopathy Program, Stanford University, School of Medicine (2013 - Present)

Boards, Advisory Committees, Professional Organizations

  • Review Board Member, United Network for Organ Sharing (2007 - 2011)
  • Vice Chair, Pediatric Council, International Society of Heart and Lung Transplantation (2010 - 2010)
  • Chair, Pediatric Council, International Society of Heart and Lung Transplantation (2011 - 2012)

Professional Education

  • Fellowship:Columbia University/New York Presbyterian Hospital (1996) NY
  • Residency:John Hopkins University School of Medicine (1996) MD
  • Medical Education:Weill Medical College Cornell University (1996) NY
  • Board Certification: Pediatric Cardiology, American Board of Pediatrics (2004)
  • Board Certification: Pediatrics, American Board of Pediatrics (1999)


Journal Articles

  • HLA desensitization with bortezomib in a highly sensitized pediatric patient PEDIATRIC TRANSPLANTATION May, L. J., Yeh, J., Maeda, K., Tyan, D. B., Chen, S., Kaufman, B. D., Bernstein, D., Rosenthal, D. N., Hollander, S. A. 2014; 18 (8): E280-E282

    View details for DOI 10.1111/petr.12347

    View details for Web of Science ID 000344360500006

  • Hypoalbuminemia and poor growth predict worse outcomes in pediatric heart transplant recipients PEDIATRIC TRANSPLANTATION Castleberry, C., White-Williams, C., Naftel, D., Tresler, M. A., Pruitt, E., Miyamoto, S. D., Murphy, D., Spicer, R., Bannister, L., Schowengerdt, K., Gilmore, L., Kaufman, B., Zangwill, S. 2014; 18 (3): 280-287


    Children with end-stage cardiac failure are at risk of HA and PG. The effects of these factors on post-transplant outcome are not well defined. Using the PHTS database, albumin and growth data from pediatric heart transplant patients from 12/1999 to 12/2009 were analyzed for effect on mortality. Covariables were examined to determine whether HA and PG were risk factors for mortality at listing and transplant. HA patients had higher waitlist mortality (15.81% vs. 10.59%, p = 0.015) with an OR of 1.59 (95% CI 1.09-2.30). Survival was worse for patients with HA at listing and transplant (p ≤ 0.01 and p = 0.026). Infants and patients with congenital heart disease did worse if they were HA at time of transplant (p = 0.020 and p = 0.028). Growth was poor while waiting with PG as risk factor for mortality in multivariate analysis (p = 0.008). HA and PG are risk factors for mortality. Survival was worse in infants and patients with congenital heart disease. PG was a risk factor for mortality in multivariate analysis. These results suggest that an opportunity may exist to improve outcomes for these patients by employing strategies to mitigate these risk factors.

    View details for DOI 10.1111/petr.12239

    View details for Web of Science ID 000333807400015

    View details for PubMedID 24646199

  • Optimal Resources for Children's Surgical Care in the United States JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS Abdullah, F., Arca, M. J., Barnhart, D. C., Berger, S., Beyer, K. M., Brandt, M. L., Byrne, D., Cassidy, L., Cavett, C. M., Chen, L. E., Evans, J., Georgeson, K. E., Goldin, A. B., Hoyt, D. B., Kaufman, B., Kueser, J., Martin, L. D., Moss, R. L., Oldham, K. T., Rangel, S. J., Ricketts, T. C., Schwartz, M. Z., Tracy, T. F., Wietecha, M., Georgeson, K. E., Houck, C. S., Goldin, A. B., Hoyt, D. B., Kaufman, B., Klein, M. D., Krummel, T. M., Kueser, J., Martin, L. D., Moss, R. L., Oldham, K. T., Rangel, S. J., Sawin, R., Wietecha, M. 2014; 218 (3): 479-?


    In summary, the Task Force does understand that change is difficult and, in the circumstance of the US health care environment, quite complex. Having acknowledged this, the Task Force firmly believes that if optimal resource standards are clear, providers will act in the best interests of their patients, infants, and children undergoing surgery in this circumstance. We intend to provide evidence to this point, to define optimal resources, and to facilitate this process. The hope and the underlying intent of these recommendations is to insure that every infant and child undergoing a surgical procedure in the United States will receive his or her care in an environment that offers all of the facilities, equipment, and, most especially, access to the professional providers who have the appropriate background and training to provide optimal care. This must be done while balancing the issues of access, staff, and the need to improve the value proposition. The Task Force is unanimous in its intent to advocate for this agenda.

    View details for DOI 10.1016/j.jamcollsurg.2013.10.028

    View details for Web of Science ID 000331718400025

    View details for PubMedID 24468231

  • Hot Topics in Tetralogy of Fallot JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Villafane, J., Feinstein, J. A., Jenkins, K. J., Vincent, R. N., Walsh, E. P., Dubin, A. M., Geva, T., Towbin, J. A., Cohen, M. S., Fraser, C., Dearani, J., Rosenthal, D., Kaufman, B., Graham, T. P. 2013; 62 (23): 2155-2166


    Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart defect. We explore "hot topics" to highlight areas of emerging science for clinicians and scientists in moving toward a better understanding of the long-term management of patients with repaired TOF. From a genetic perspective, the etiology of TOF is multifactorial, with a familial recurrence risk of 3%. Cardiac magnetic resonance is the gold standard assessment tool based on its superior imaging of the right ventricular (RV) outflow tract, pulmonary arteries, aorta, and aortopulmonary collaterals, and on its ability to quantify biventricular size and function, pulmonary regurgitation (PR), and myocardial viability. Atrial re-entrant tachycardia will develop in more than 30% of patients, and high-grade ventricular arrhythmias will be seen in about 10% of patients. The overall incidence of sudden cardiac death is estimated at 0.2%/yr. Risk stratification, even with electrophysiologic testing and cardiac magnetic resonance, remains imperfect. Drug therapy has largely been abandoned, and defibrillator placement, despite its high risks for complications and inappropriate discharges, is often recommended for patients at higher risk. Definitive information about optimal surgical strategies for primary repair to preserve RV function, reduce arrhythmia, and optimize functional status is lacking. Post-operative lesions are often amenable to transcatheter intervention. In selected cases, PR may be treated with transcatheter valve insertion. Ongoing surveillance of RV function is a crucial component of clinical assessment. Except for resynchronization with biventricular pacing, no medical therapies have been shown to be effective after RV dysfunction occurs. In patients with significant PR with RV dilation, optimal timing of pulmonary valve replacement remains uncertain, although accepted criteria are emerging.

    View details for DOI 10.1016/j.jacc.2013.07.100

    View details for Web of Science ID 000328073000002

  • Adult and pediatric perspectives on heart retransplant. World journal for pediatric & congenital heart surgery Kaufman, B. D., Jessup, M. 2013; 4 (1): 75-79


    At the Ethics of the Heart II: Ethical and Policy Challenges in Congenital Heart Disease Conference, March 16-17, 2012 in Philadelphia, Pennsylvania, one of the sessions focused on the issues related to end-stage heart failure in patients with congenital heart disease including utilizing the therapy of heart transplantation. This article will summarize the session related to repeat heart transplant that was based on discussion of actual patient cases, two adults and one pediatric, presented, respectively, by an adult and a pediatric heart transplant specialist. Outcome data related to retransplant for both adult and pediatric heart transplant populations are reviewed. The complicated ethical issues related to considerations of beneficence versus nonmalfeasance by a medical care team for an individual patient, patient autonomy related to adherence, and obligations to society to fairly allocate the scarce precious resource of donor organs are discussed.

    View details for DOI 10.1177/2150135112469972

    View details for PubMedID 23799759

Stanford Medicine Resources: